Post by
AngelaL on Apr 27, 2021 5:01am
Buyout?
The biotech public market is on fire in NYC and London - soaring market valuations and lots of acquisitions. Claritas is really well positioned with R-107 to be taken out: novel first-in-class drug for covid and PAH, orphan drug indication for PAH, current market entrants are unsatisfactory so PAH represents a major unmet medical need, clear and novel biological mechanism of action, world-class Board of Directors and Scientific Advisory Board, imminent start of clinical trials, superior features of R-107 vs all known competitors in terms of duration of action and magnitude of effect and reversal of underlying disease, very rapid proof of concept study planned for pilot Phase 2 next year.
Comment by
indaknownewfie on Apr 27, 2021 6:42am
You are spot on. The sharks are circling in the biotech world for sure.